Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.

Oostdijk W, Hümmelink R, Odink RJ, Partsch CJ, Drop SL, Lorenzen F, Sippell WG, van der Velde EA, Schultheiss H

European journal of pediatrics1 Feb 1990Cited by 32 (Europe PMC)

PMID2138079DOI10.1007/bf02171554PepBankPUB-02138079

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, basal LH decreased in both prior-treatment groups after Decapeptyl-Depot therapy.
In plain wordsIn children with early puberty, basal LH decreased in both prior-treatment groups during Decapeptyl-Depot treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBasal LH
Study
n = 51
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Basal plasma luteinizing hormone (LH) levels decreased in both groups after 1 year of therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807901
02HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, the LH response to intravenous GnRH decreased in both groups during Decapeptyl-Depot treatment.
In plain wordsIn children with early puberty, stimulated LH decreased in both groups during Decapeptyl-Depot treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseStimulated LH
Study
n = 51
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
The LH response to intravenous GnRH was reduced in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807902
03HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, basal FSH decreased in both groups during Decapeptyl-Depot treatment.
In plain wordsIn children with early puberty, basal FSH decreased in both groups during Decapeptyl-Depot treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBasal FSH
Study
n = 51
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Basal plasma follicle stimulating hormone (FSH) levels decreased in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807903
04HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, stimulated FSH decreased in both groups after Decapeptyl-Depot treatment.
In plain wordsIn children with early puberty, stimulated FSH decreased in both groups during Decapeptyl-Depot treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseStimulated FSH
Study
n = 51
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Stimulated FSH levels were reduced in both groups after 1 year of DD treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807904
05HumanNon-randomized trialEfficacy outcome
In girls with central precocious puberty, oestradiol decreased to prepubertal levels in both groups during Decapeptyl-Depot treatment.
In plain wordsIn girls with early puberty, oestradiol fell to prepubertal levels in both groups during Decapeptyl-Depot treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePlasma oestradiol
Study
n = 44
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Plasma oestradiol levels in the girls decreased to prepubertal levels in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807905
06HumanNon-randomized trialEfficacy outcome
In children receiving Decapeptyl-Depot, clinical gonadarche signs did not progress and sometimes regressed.
In plain wordsIn children receiving Decapeptyl-Depot, signs of early puberty did not progress and sometimes regressed.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedClinical gonadarche progression
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
In all patients the clinical signs of precocious gonadarche such as breast development and menstruations (girls) and an increased testis volume (boys), did not further progress and sometimes regressed in several patients.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807906
07HumanNon-randomized trialEfficacy outcome
In previously untreated girls with central precocious puberty, growth velocity fell from 9.0 cm/year before treatment to 6.3 in the first half-year and 4.5 in the second half-year of Decapeptyl-Depot.
In plain wordsIn previously untreated girls, growth slowed from 9.0 cm/year before treatment to 6.3, then 4.5, in the first and second half-years of Decapeptyl-Depot.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGrowth velocity in previously untreated girls
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · first and second half-year of treatmentAs given in this study (human).
Measurements
Growth velocity
9 cm/year
last half-year before treatment, previously untreated girls
Growth velocity
6.3 cm/year
first half-year of treatment
Growth velocity
4.5 cm/year
second half-year of treatment
Source sentences
Summary
Growth velocity decreased in the girls of group 1 from 9.0 +/- 0.72 cm/year (mean +/- SEM) in the last half-year before treatment to 6.3 +/- 0.50 in the first half-year of treatment (P less than 0.01) and to 4.5 +/- 0.23 cm/year in the second half-year (P less than 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807907
08HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, growth velocity stabilized after 12 months of Decapeptyl-Depot treatment.
In plain wordsIn children with early puberty, growth stabilized after 12 months of Decapeptyl-Depot treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableGrowth velocity stabilization
Study
n: not reported in source
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
After 12 months a stabilization of growth velocity was observed.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD).
Summary · context
Fifty-one patients (44 girls, 7 boys) were treated with DD for 12 months or more.
Report a problemFND-0213807909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.